Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the US for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999–2002. Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. 10.1161/circ.1 Search in Google Scholarħ. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. 10.1093/eurheartj/ehr225 Search in Google ScholarĦ. Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Angelakopoulou A, Shah T, Sofat R, Shah S, Berry DJ, Cooper J, et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Kizer JR, Madias C, Wilner B, Vaughan CJ, Mushlin AI, Trushin P, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Lipoproteins, cardiovascular disease, and death. Gordon T, Kannel WB, Castelli WP, Dawber TR. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Kannel WB, Castelli WP, Gordon T, McNamara PM. Writing support was provided by Jim Ascencio, a native English speaker.Īuthor contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.įinancial support: This study was funded by grants from the National Science Council (NSC 101-2314-B-075A-006-MY3) and Taichung Veterans General Hospital, Taichung, Taiwan, ROC (TCVGH-1030101C TCVGH-1020101C TCVGH-1013001C TCVGH-1003001C).Ĭompeting interests: The funding organisation(s) played no role in the study design in the collection, analysis, and interpretation of data in the writing of the report or in the decision to submit the report for publication. The authors would like to thank the Clinical Informatics Research & Development Center of Taichung Veterans General Hospital, Taichung, Taiwan, for data collection (F14043, F14051). The NF is simple and may be used for screening as well as for follow-up of patients on lipid lowering agents. –0.23 to –0.30 mmol/L p7.74 mmol/L, respectively.Ĭonclusions: In the Chinese population, the accuracy of eLDL-C measurement with the NF was better than that with the FF, especially in subjects with TC levels between 2.58 and 7.74 mmol/L. For the subjects with TC between 2.58 and 7.74 mmol/L, the difference between mLDL-C and eLDL-C using the NF was less than that from the FF (testing group: –0.04 to –0.20 vs. Results: The NF yielded an estimated LDL-C (eLDL-C) equal to 0.75×total cholesterol–0.6465 (mmol/L). Linear regression analysis was used in the testing group to investigate the association between measured LDL-C (mLDL-C) and TC concentration, and was verified in the validation group. Methods: This cross-sectional study enrolled two study populations (a testing group, n=16,749, and a validation group, n=4940). We aimed to develop a new and simple formula (NF) for LDL-C estimation. Background: Low-density lipoprotein cholesterol (LDL-C) is an established risk factor for cardiovascular disease and is usually estimated by the Friedewald formula (FF) calculated from three parameters, namely, total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |